Sector
PharmaceuticalsOpen
₹352.8Prev. Close
₹350.15Turnover(Lac.)
₹35.17Day's High
₹368Day's Low
₹351.652 Week's High
₹404.9552 Week's Low
₹299.95Book Value
₹150.92Face Value
₹10Mkt Cap (₹ Cr.)
574.14P/E
23.93EPS
14.57Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 16.08 | 20.58 | 18.08 | 15.49 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 206.84 | 175.35 | 159.95 | 147.44 |
Net Worth | 222.92 | 195.93 | 178.03 | 162.93 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Revenue | 70.01 | 60.76 | 96.41 | 50.45 |
yoy growth (%) | 15.21 | -36.97 | 91.08 | 79.31 |
Raw materials | -39.06 | -35.75 | -52.98 | -25.9 |
As % of sales | 55.79 | 58.83 | 54.95 | 51.34 |
Employee costs | -5.21 | -5.65 | -5.22 | -4.21 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 7.5 | 5.22 | 19.52 | 7.15 |
Depreciation | -1.14 | -1.15 | -1.2 | -1.19 |
Tax paid | -1.35 | -0.76 | -4.75 | -0.96 |
Working capital | -1.1 | -5.99 | 6.43 | 6.49 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 15.21 | -36.97 | 91.08 | 79.31 |
Op profit growth | 276.91 | -91.66 | 197.85 | -2,095.55 |
EBIT growth | 39.14 | -70.16 | 178.12 | -1,655.73 |
Net profit growth | 38.1 | -69.81 | 138.33 | -17,121.7 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 154.37 | 139.6 | 114.23 | 68.52 | 53.32 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 154.37 | 139.6 | 114.23 | 68.52 | 53.32 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 4.48 | 2.92 | 2.91 | 2.67 | 4.13 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,788.8 | 136.25 | 4,29,217.03 | 1,181.05 | 0.75 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,924.5 | 75.78 | 1,57,100.32 | 594 | 0.51 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,533.7 | 26.61 | 1,23,852.12 | 1,438.15 | 0.85 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,332.4 | 61.86 | 1,12,844.49 | 485 | 0.84 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,545.5 | 54.3 | 1,05,003.3 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Mukund P Mehta
Whole-time Director
Bhavin M Mehta
Independent Director
Hemang Engineer
Managing Director
Mira Bhavin Mehta
Independent Director
Murti Vasudev Krishna
Independent Director
Venkita Subramanian Rajan
Company Sec. & Compli. Officer
Pushpa Nyoupane
Independent Director
Dipen Jayantilal Jain
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Kilitch Drugs (India) Ltd
Summary
Kilitch Drugs (India) Limited (KDIL), incorporated in May, 1992 is the one of the leading and fastest growing pharmaceutical companies in the world, manufacturing, supplying and marketing broad range of pharmaceutical formulations in the various dosage forms like Solid, Liquid and Parental across the globe. Their extensive research efforts have led to development of comprehensive, diverse and highly complementary portfolio of medicines targeting a wide spectrum of chronic and acute treatments which includes Sterile dosages namely Injectables & Ophthalmic, Effervescent tablets & Granules, Tablets & Capsules, OTC range covering varied Nutraceuticals & Cosmetics and Medical devices.The Company is engaged in development, manufacturing and marketing of quality finished dosages. The Company is one of the most reliable manufacturer of injectables in India and one of the largest manufacturer of cephalosporins in Africa having its manufacturing unit located in India and Ethiopia. Its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms of creating safe pharmaceutical solutions.The Company went public in Feb.94 to set up a pharmaceutical formulation plant at Thane to manufacture pharmaceutical products in the form of tablets, capsules,liquid orals, ointments, creams and injectables. Even before the plant was commissioned, the company came out with a rights issue in Oct.95 to expand the injectible capacity. Com
Read More
The Kilitch Drugs India Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹357 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Kilitch Drugs India Ltd is ₹574.14 Cr. as of 24 Apr ‘25
The PE and PB ratios of Kilitch Drugs India Ltd is 23.93 and 2.37 as of 24 Apr ‘25
The 52-week high/low is the highest and lowest price at which a Kilitch Drugs India Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Kilitch Drugs India Ltd is ₹299.95 and ₹404.95 as of 24 Apr ‘25
Kilitch Drugs India Ltd's CAGR for 5 Years at 27.67%, 3 Years at 21.71%, 1 Year at -0.36%, 6 Month at 12.21%, 3 Month at 6.01% and 1 Month at -3.37%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.